These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21305272)

  • 1. In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance.
    Wattanachai N; Polasek TM; Heath TM; Uchaipichat V; Tassaneeyakul W; Tassaneeyakul W; Miners JO
    Eur J Clin Pharmacol; 2011 Aug; 67(8):815-24. PubMed ID: 21305272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9.
    Rowland A; Elliot DJ; Knights KM; Mackenzie PI; Miners JO
    Drug Metab Dispos; 2008 May; 36(5):870-7. PubMed ID: 18256202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
    Wattanachai N; Tassaneeyakul W; Rowland A; Elliot DJ; Bowalgaha K; Knights KM; Miners JO
    Drug Metab Dispos; 2012 May; 40(5):982-9. PubMed ID: 22331994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.
    Tsukada C; Saito T; Maekawa M; Mano N; Oda A; Hirasawa N; Hiratsuka M
    Drug Metab Pharmacokinet; 2015 Oct; 30(5):366-73. PubMed ID: 26427316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of buffer conditions on CYP2C8-mediated paclitaxel 6α-hydroxylation and CYP3A4-mediated triazolam α- and 4-hydroxylation by human liver microsomes.
    Kudo T; Ozaki Y; Kusano T; Hotta E; Oya Y; Komatsu S; Goda H; Ito K
    Xenobiotica; 2016; 46(3):241-6. PubMed ID: 26290405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials.
    Wang Y; Wang M; Qi H; Pan P; Hou T; Li J; He G; Zhang H
    Drug Metab Dispos; 2014 Apr; 42(4):782-95. PubMed ID: 24476576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0% w/v) and in vitro - in vivo extrapolation of hepatic clearance.
    Palacharla RC; Uthukam V; Manoharan A; Ponnamaneni RK; Padala NP; Boggavarapu RK; Bhyrapuneni G; Ajjala DR; Nirogi R
    Eur J Pharm Sci; 2017 Apr; 101():80-89. PubMed ID: 28179134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity.
    Kerdpin O; Elliot DJ; Boye SL; Birkett DJ; Yoovathaworn K; Miners JO
    Biochemistry; 2004 Jun; 43(24):7834-42. PubMed ID: 15196026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro.
    Polasek TM; Elliot DJ; Lewis BC; Miners JO
    J Pharmacol Exp Ther; 2004 Dec; 311(3):996-1007. PubMed ID: 15304522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel.
    Hanioka N; Matsumoto K; Saito Y; Narimatsu S
    Basic Clin Pharmacol Toxicol; 2010 Jul; 107(1):565-9. PubMed ID: 20148860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-performance liquid chromatography analysis of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation.
    Crespi CL; Chang TK; Waxman DJ
    Methods Mol Biol; 2006; 320():103-7. PubMed ID: 16719379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants.
    Václavíková R; Horský S; Simek P; Gut I
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Sep; 368(3):200-9. PubMed ID: 12920504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.
    Fransson MN; Gréen H; Litton JE; Friberg LE
    Drug Metab Dispos; 2011 Feb; 39(2):247-55. PubMed ID: 21056987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population.
    Saito Y; Katori N; Soyama A; Nakajima Y; Yoshitani T; Kim SR; Fukushima-Uesaka H; Kurose K; Kaniwa N; Ozawa S; Kamatani N; Komamura K; Kamakura S; Kitakaze M; Tomoike H; Sugai K; Minami N; Kimura H; Goto Y; Minami H; Yoshida T; Kunitoh H; Ohe Y; Yamamoto N; Tamura T; Saijo N; Sawada J
    Pharmacogenet Genomics; 2007 Jul; 17(7):461-71. PubMed ID: 17558302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation.
    Rowbotham SE; Boddy AV; Redfern CP; Veal GJ; Daly AK
    Drug Metab Dispos; 2010 Aug; 38(8):1261-6. PubMed ID: 20421446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro.
    Yu L; Shi D; Ma L; Zhou Q; Zeng S
    Biopharm Drug Dispos; 2013 Jul; 34(5):278-87. PubMed ID: 23536207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate.
    Li XQ; Björkman A; Andersson TB; Ridderström M; Masimirembwa CM
    J Pharmacol Exp Ther; 2002 Feb; 300(2):399-407. PubMed ID: 11805197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.
    Mukai Y; Senda A; Toda T; Eliasson E; Rane A; Inotsume N
    Basic Clin Pharmacol Toxicol; 2016 Jun; 118(6):408-14. PubMed ID: 26551762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
    Henningsson A; Marsh S; Loos WJ; Karlsson MO; Garsa A; Mross K; Mielke S; Viganò L; Locatelli A; Verweij J; Sparreboom A; McLeod HL
    Clin Cancer Res; 2005 Nov; 11(22):8097-104. PubMed ID: 16299241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants.
    Melet A; Marques-Soares C; Schoch GA; Macherey AC; Jaouen M; Dansette PM; Sari MA; Johnson EF; Mansuy D
    Biochemistry; 2004 Dec; 43(49):15379-92. PubMed ID: 15581350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.